Cancer patients still facing ‘dangerous treatment delays', experts warn
It comes as new figures show the proportion of patients who had cancer diagnosed or ruled out within 28 days has declined for the third consecutive month, while those waiting no longer than 62 days for their first treatment also fell.
Monthly data published by the NHS shows 74.8% of patients urgently referred for suspected cancer were diagnosed or had cancer ruled out within 28 days in May, down from 76.7% in April and the third monthly fall in a row.
The Government and NHS England have set a target of March 2026 for this figure to reach 80%.
Elsewhere, the proportion of patients who had waited no longer than 62 days in May from an urgent suspected cancer referral, or consultant upgrade, to their first definitive treatment for cancer was 67.8%, down from 69.9% in April.
The target to reach 75% is also March 2026.
Professor Pat Price, oncologist and chairwoman of Radiotherapy UK, said: 'Today's cancer waiting times show yet another missed opportunity to put a stop to dangerous treatment delays.
'Patients should not be kept on the edge of their seats waiting for the chance to access the life-saving treatment they need.
'It's an unfortunate reality that these delays have become normalised.'
Kate Seymour, head of external affairs at Macmillan Cancer Support, said: 'Behind these delays in cancer diagnosis are thousands of people hoping for clarity, support and the chance to move forward.
'Right now, many people are experiencing differences in care depending on who they are or where they live, which is completely unacceptable.
'Everyone facing cancer deserves the very best care, as quickly as possible, no matter their postcode, background, or circumstances.
Ms Seymour added that the upcoming National Cancer Plan for England 'is a real chance to make things better'.
The Department of Health and Social Care launched a call for evidence to help shape a national cancer plan in February.
The blueprint is expected to be published later this year and will aim to transform cancer care by improving diagnosis, screening and treatment, as well as bolstering research and looking at ways to help prevent the disease.
An NHS spokesperson said: 'Despite the NHS seeing and treating record numbers of people for cancer, with more people diagnosed at an earlier stage than ever before, we know there is more to do to improve early diagnosis, access to tests and life-saving treatments.
'Our 10 Year Health Plan launched last week sets out some of the ways we will transform cancer care to be fit for the future, including innovation to speed up referral and diagnosis, with more to follow in the National Cancer Plan coming later this year.'
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Grand Forks lawmaker resigns to join North Dakota Department of Health and Human Services
State Rep. Emily O'Brien, R-Grand Forks, speaks to other lawmakers during a meeting of the Legislative Management Committee on the House Floor on Nov. 13, 2024. (Michael Achterling/North Dakota Monitor) Rep. Emily O'Brien, R-Grand Forks, is leaving her legislative seat to become second-in-command at the North Dakota Department of Health and Human Services. O'Brien starts her new job as deputy commissioner of the department Wednesday. According to a Tuesday announcement from the agency, she will serve as a liaison between Health and Human Services and the Legislature, and oversee a funding and performance tracking system. O'Brien's resignation from the Legislature takes effect Tuesday, according to a Monday letter she sent to Legislative Council and legislative leaders. 'This role will allow me to continue serving our state, but in a different capacity — one that complements the work we have done together in the Legislature to strengthen the health, well-being, and future of North Dakotans,' O'Brien wrote in the letter. O'Brien was first elected to represent District 42 in the North Dakota House in 2016, winning her bids for reelection in 2020 and 2024. She served on the Human Resources Division of the House Appropriations Committee, which works on the Department of Health and Human Services budget, during the 2023 and 2025 legislative sessions. O'Brien also chaired the Legislative Audit and Fiscal Review Committee over the 2023-2025 interim session, and served as its vice chair for the 2021-2023 and 2025-2027 interim sessions. During the 2023-2025 interim, she served on the Health Care and Health Services committees. 'We are thrilled to welcome Emily as our new deputy,' Pat Traynor, interim commissioner, said in the Tuesday announcement. 'She brings a proven track record of leadership, deep experience in public service, and a strong commitment to using data to guide decisions.' The North Dakota Constitution forbids members of the Legislature from holding a full-time appointed position at the state level. It'll be up to the District 42 Republican Party to fill O'Brien's seat, Legislative Council Director John Bjornson said in an email. Once the district leaders receive an official letter from Legislative Management notifying them of the vacancy, they will have three weeks to name a temporary replacement. That replacement will serve until the 2026 general election, during which voters will elect someone to serve the final two years of O'Brien's term, Bjornson said. Solve the daily Crossword
Forbes
2 hours ago
- Forbes
The Science Behind The Fight Over 7-OH
Drug policy is an easy thing to get wrong and a difficult thing to get right. Most drug policy experts agree that total prohibition has failed, but there is little consensus on what might actually work. Drug policy often happens in the ivory towers of government and academia, which can lead to a gap between official rules and street reality—the best example being alcohol remaining legal while less harmful drugs are banned. Why ban a less harmful compound like cannabis when booze is cheap and widely available to adults? And, yet, cannabis is banned at the federal level despite hundreds of human trials showing medical value—a decision rooted more in 'reefer madness' hysteria than science. Now a similar fight may be brewing over a newer compound: 7-hydroxymitragynine (7-OH). 7-OH is a naturally occurring alkaloid found in trace amounts in the kratom plant. Both kratom and 7-OH are mildly psychoactive and sold in smoke shops across much of the U.S. The effects can be either stimulative or sedative, depending on dose and individual metabolism. Why people turn to these products varies greatly but many report doing so for medicinal reasons. In the last couple of years, labs have begun extracting and concentrating 7-OH for sale as a standalone product. Both of these compounds have experienced their share of controversy, which seems to be growing. On July 29th, the Food and Drug Administration (FDA) issued an emergency request to the Drug Enforcement Administration (DEA) to place 7-OH into the most restrictive class in the Controlled Substances Act (CSA)—the same category as heroin. The FDA cited increased risks of dependency given the way 7-OH binds with mu opioid receptors and anecdotal reports of misuse from social media. The FDA has concerns about the potential of 7-OH to be abused and cause harm. 'Today, we're taking action on 7-OH as a critical step in the fight against opioid addiction,' said U.S. Health and Human Services Secretary Robert F. Kennedy, Jr. 'We will protect the health of our nation's youth as we advance our mission to Make America Healthy Again.' The FDA did not request a ban on kratom in its natural form, but because 7-OH is part of kratom's chemistry, any action could have legal spillover effects on kratom itself. Louisiana recently banned both in one move. The DEA can either grant the FDA's emergency scheduling request, removing 7-OH from store shelves immediately, or they may start the normal rulemaking process, which takes 12–18 months. It's an exhaustive process that examines both the scientific data of a compound and citizens' personal experiences with it. There are also public comments and hearings designed to maximize due diligence before the DEA schedules any compound. Congress can also act, but most scheduling decisions are made within the agencies. The DEA may be reluctant to do so this time, given the recent past. The DEA and the FDA already tried to ban the kratom plant in 2016 but withdrew during the process after receiving over 20,000 public comments from advocates, patients, and scientists. Kratom (and 7-OH) may be used by tens of thousands of patients for pain relief and harm reduction. The outcry from these patients was significant enough to cause the FDA to rescind their recommendation to ban both 7-OH and kratom. The FDA Assistant Secretary of Health at the time, Dr. Brett Giroir, concluded more scientific studies were needed before kratom could be credibly banned. He sent a letter to the acting DEA Administrator rescinding the FDA recommendation to place kratom in Schedule 1 of the CSA. While the letter is wonky to read, Girori listed several important scheduling considerations in his letter: 'Further analysis and public input regarding kratom and its chemical components are needed before any scheduling should be undertaken. It is important that we have additional information to justify scheduling, such as: While some of the studies and data that Giroir wanted on kratom and 7-OH may be underway, most of the items he listed are still unknown and no credible data exists to meet the standards cited in his rescinding letter. In the years since, even more people have turned to these compounds for relief, making banning them more complicated than in 2016. One patient I spoke with who uses 7-OH is Zach L., who did not want his last name used for this article. He's struggled with opioid dependency for a long time. 'For the past 10 years, I battled opioid addiction. Fake pills. Xanax. Anything to quiet the storm in my head,' Zach said. 'I overdosed four times. I went to rehab twice.' Then he found 7-OH and things began to improve for him. 'The first time I took it, something changed,' said Zach. 'I didn't feel high. I felt normal. Present. The cravings quieted. The bottomless pit of anxiety and depression eased. For the first time in a decade, I could see a future that didn't end in relapse or worse.' For Zach, 7-OH is a life saver and he believes it's much safer than hard drugs and alcohol. The most recent data available may indicate that kratom and 7-OH are relatively safe compared to legal drugs like alcohol. This data from the 2023 National Poison Data System (NPDS) may be informative to policymakers: Compare this to alcohol: While none of the PhDs I spoke with about 7-OH advocate banning alcohol in this country again, some were troubled by the lack of data the FDA cited in the press release. 'There is not sufficient scientific information or data to meet the criteria for scheduling,' said Dr. Kirsten Smith of John Hopkins University. Dr. Smith works with people with drug-use disorders and takes a real world view of drug policy. She's concerned about what some addicts or chronic pain patients might do if a ban of 7-OH happens. 'People will find something else to use if this is banned and those alternatives may be more harmful than 7-OH.' Dr. Edwin Boyer, Professor of Emergency Medicine at Ohio State University, shared Dr. Smith's concerns about the FDA analysis. 'The problem with the Food and Drug Administration analysis is that it relies heavily on the strength of binding at the mu opioid receptor,' said Dr. Boyer. 'In reality, toxicity is driven by exposure, not strength of binding. The FDA did not consider the degree of exposure following oral administration of 7-hydroxymitragynine in their analysis.' According to a recent article in Reuters, The Marwood Group, a health industry advisory firm, recently completed an independent analysis of data from the FDA, CDC, and other federal agencies that confirms 7-OH's strong real-world safety profile. According to the FDA's Adverse Event Reporting System, there have been no confirmed deaths from 7-OH alone despite more than half a billion estimated doses consumed nationwide. While the Marwood Group may harbor their own biases, one element of the report was striking. Opioid deaths were down significantly across the country in 2023 and 2024. While the availability of Narcan, a drug that reverses overdoses if administered quickly enough, has grown since 2022, it's not at the same rate as the drop in overdose deaths. The report suggested that the increased availability of 7-OH may be contributing to saving lives. The charts, graphs, and patient testimonials in the report are compelling. While the drop in overdose deaths is unquestionably good news, no one really knows why it's happening. While the availability of 7-OH cannot be dismissed as a root cause, like most things regarding 7-OH, its impact on overdose deaths has not yet been measured or studied. In a world where prohibition has failed and legal drugs like alcohol cause massive harm, should a compound with no confirmed fatalities—and potential public health benefits—be banned without more research? Wouldn't science, not panic, lead to better policy?
Forbes
2 hours ago
- Forbes
Science Or Hysteria? The Fight Over 7-OH
Drug policy is an easy thing to get wrong and a difficult thing to get right. Most drug policy experts agree that total prohibition has failed, but there is little consensus on what might actually work. Drug policy often happens in the ivory towers of government and academia, which can lead to a gap between official rules and street reality—the best example being alcohol remaining legal while less harmful drugs are banned. Why ban a less harmful compound like cannabis when booze is cheap and widely available to adults? And, yet, cannabis is banned at the federal level despite hundreds of human trials showing medical value—a decision rooted more in 'reefer madness' hysteria than science. Now a similar fight may be brewing over a newer compound: 7-hydroxymitragynine (7-OH). 7-OH is a naturally occurring alkaloid found in trace amounts in the kratom plant. Both kratom and 7-OH are mildly psychoactive and sold in smoke shops across much of the U.S. The effects can be either stimulative or sedative, depending on dose and individual metabolism. Why people turn to these products varies greatly but many report doing so for medicinal reasons. In the last couple of years, labs have begun extracting and concentrating 7-OH for sale as a standalone product. Both of these compounds have experienced their share of controversy, which seems to be growing. On July 29th, the Food and Drug Administration (FDA) issued an emergency request to the Drug Enforcement Administration (DEA) to place 7-OH into the most restrictive class in the Controlled Substances Act (CSA)—the same category as heroin. The FDA cited increased risks of dependency given the way 7-OH binds with mu opioid receptors and anecdotal reports of misuse from social media. The FDA has concerns about the potential of 7-OH to be abused and cause harm. 'Today, we're taking action on 7-OH as a critical step in the fight against opioid addiction,' said U.S. Health and Human Services Secretary Robert F. Kennedy, Jr. 'We will protect the health of our nation's youth as we advance our mission to Make America Healthy Again.' The FDA did not request a ban on kratom in its natural form, but because 7-OH is part of kratom's chemistry, any action could have legal spillover effects on kratom itself. Louisiana recently banned both in one move. The DEA can either grant the FDA's emergency scheduling request, removing 7-OH from store shelves immediately, or they may start the normal rulemaking process, which takes 12–18 months. It's an exhaustive process that examines both the scientific data of a compound and citizens' personal experiences with it. There are also public comments and hearings designed to maximize due diligence before the DEA schedules any compound. Congress can also act, but most scheduling decisions are made within the agencies. The DEA may be reluctant to do so this time, given the recent past. The DEA and the FDA already tried to ban the kratom plant in 2016 but withdrew during the process after receiving over 20,000 public comments from advocates, patients, and scientists. Kratom (and 7-OH) may be used by tens of thousands of patients for pain relief and harm reduction. The outcry from these patients was significant enough to cause the FDA to rescind their recommendation to ban both 7-OH and kratom. The FDA Assistant Secretary of Health at the time, Dr. Brett Giroir, concluded more scientific studies were needed before kratom could be credibly banned. He sent a letter to the acting DEA Administrator rescinding the FDA recommendation to place kratom in Schedule 1 of the CSA. While the letter is wonky to read, Girori listed several important scheduling considerations in his letter: 'Further analysis and public input regarding kratom and its chemical components are needed before any scheduling should be undertaken. It is important that we have additional information to justify scheduling, such as: While some of the studies and data that Giroir wanted on kratom and 7-OH may be underway, most of the items he listed are still unknown and no credible data exists to meet the standards cited in his rescinding letter. In the years since, even more people have turned to these compounds for relief, making banning them more complicated than in 2016. One patient I spoke with who uses 7-OH is Zach L., who did not want his last name used for this article. He's struggled with opioid dependency for a long time. 'For the past 10 years, I battled opioid addiction. Fake pills. Xanax. Anything to quiet the storm in my head,' Zach said. 'I overdosed four times. I went to rehab twice.' Then he found 7-OH and things began to improve for him. 'The first time I took it, something changed,' said Zach. 'I didn't feel high. I felt normal. Present. The cravings quieted. The bottomless pit of anxiety and depression eased. For the first time in a decade, I could see a future that didn't end in relapse or worse.' For Zach, 7-OH is a life saver and he believes it's much safer than hard drugs and alcohol. The most recent data available may indicate that kratom and 7-OH are relatively safe compared to legal drugs like alcohol. This data from the 2023 National Poison Data System (NPDS) may be informative to policymakers: Compare this to alcohol: While none of the PhDs I spoke with about 7-OH advocate banning alcohol in this country again, some were troubled by the lack of data the FDA cited in the press release. 'There is not sufficient scientific information or data to meet the criteria for scheduling,' said Dr. Kirsten Smith of John Hopkins University. Dr. Smith works with people with drug-use disorders and takes a real world view of drug policy. She's concerned about what some addicts or chronic pain patients might do if a ban of 7-OH happens. 'People will find something else to use if this is banned and those alternatives may be more harmful than 7-OH.' Dr. Edwin Boyer, Professor of Emergency Medicine at Ohio State University, shared Dr. Smith's concerns about the FDA analysis. 'The problem with the Food and Drug Administration analysis is that it relies heavily on the strength of binding at the mu opioid receptor,' said Dr. Boyer. 'In reality, toxicity is driven by exposure, not strength of binding. The FDA did not consider the degree of exposure following oral administration of 7-hydroxymitragynine in their analysis.' According to a recent article in Reuters, The Marwood Group, a health industry advisory firm, recently completed an independent analysis of data from the FDA, CDC, and other federal agencies that confirms 7-OH's strong real-world safety profile. According to the FDA's Adverse Event Reporting System, there have been no confirmed deaths from 7-OH alone despite more than half a billion estimated doses consumed nationwide. While the Marwood Group may harbor their own biases, one element of the report was striking. Opioid deaths were down significantly across the country in 2023 and 2024. While the availability of Narcan, a drug that reverses overdoses if administered quickly enough, has grown since 2022, it's not at the same rate as the drop in overdose deaths. The report suggested that the increased availability of 7-OH may be contributing to saving lives. The charts, graphs, and patient testimonials in the report are compelling. While the drop in overdose deaths is unquestionably good news, no one really knows why it's happening. While the availability of 7-OH cannot be dismissed as a root cause, like most things regarding 7-OH, its impact on overdose deaths has not yet been measured or studied. In a world where prohibition has failed and legal drugs like alcohol cause massive harm, should a compound with no confirmed fatalities—and potential public health benefits—be banned without more research? Wouldn't science, not panic, lead to better policy?
